Spelling suggestions: "subject:"demyelinating diseases -- pathology."" "subject:"demyelinating iseases -- pathology.""
1 |
Measurement of brain atrophy in pediatric patients with clinically isolated demyelinating syndromes and multiple sclerosisBelzycki, Sari E. January 2007 (has links)
Brain atrophy has been used as a marker for disease progression in Multiple Sclerosis (MS). SIENA, an automated tool for measuring brain volume change, was tested to see whether MRI slice thickness and gap presence affect longitudinal atrophy measures. Isotropic global scan-rescan images were used to simulate 3 mm and 5 mm axial slice thicknesses with 1 and 2mm gaps, respectively. SIENA remained accurate and precise with increasing slice thickness and gap presence. Furthermore, symmetric pre-registration was crucial for scans with larger slice-thickness and gaps. / SIENA was used to observe atrophy in children who have experienced a Clinically Isolated Syndrome (CIS) of the type leading to MS (CIS-MS). Brain atrophy was present within the first three months after a CIS event, and then subsided over the rest of the year. If the first acute episode was excluded, there was no significant difference in atrophy rates between the CIS-MS group and the CIS group, and no significant difference between those with T2-weighted brain lesions versus those who had none.
|
2 |
Measurement of brain atrophy in pediatric patients with clinically isolated demyelinating syndromes and multiple sclerosisBelzycki, Sari E. January 2007 (has links)
No description available.
|
Page generated in 0.1141 seconds